Fulcrum Therapeutics (NASDAQ:FULC) is now covered by analysts at JPMorgan Chase & Co.. They set an "overweight" rating and a $20.00 price target on the stock.
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Fulcrum Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference
Bullish Analyst Sentiment on Fulcrum Therapeutics (FULC) Following Positive Updates from Phase 1b PIONEER Study [Yahoo! Finance]
Fulcrum Therapeutics (NASDAQ:FULC) was given a new $18.00 price target on by analysts at Truist Financial Corporation.